Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer

CONCLUSIONS: Pembrolizumab is a highly cost-effective treatment option when compared with chemotherapy for women with previously treated dMMR/MSI-H unresectable or mEC. Results were robust to the changes in parameters and assumptions explored.PMID:33866938 | DOI:10.1080/13696998.2021.1917140

Source: Journal of Medical Economics - April 19, 2021 Category: Health Management Authors: Elizabeth Thurgar Mark Gouldson Suzette Matthijsse Mayur Amonkar Patricia Marinello Navneet Upadhyay Chizoba Nwankwo Raquel Aguiar-Ib áñez Source Type: research